The cellular pharmacodynamic effects of IDO1 activity include the inhibition of antigen-specific CD8+ T cell proliferation [24–26], stimulation of differentiation of naïve CD4+ T cells to FoxP3+ regulatory T cells (Tregs) [27, 28], the activation of Tregs [29], and the recruitment of MDSC to the tumor [30]. Here, IDO1 is linked to neoplasm.